QC6352, once considered “best-in-class,” has a hidden liability. New research shows it is a dual KDM4–DHODH inhibitor, with DHODH driving activity in glioblastoma models. We’re updating the Chemical Probes Portal with a warning and guidance on controls. #DrugDiscovery
www.nature.com/articles/s41...
nature.com
DHODH is the key target of the KDM4 inhibitor QC6352 in glioblastoma stem cells - Nature Chemical Biology
QC6352, originally developed as a KDM4 inhibitor, exerts its anticancer activity in glioblastoma models primarily through inhibition of dihydroorotate dehydrogenase, a key enzyme in de novo pyrimidine...
